REQUEST FOR APPLICATIONS

OHSU Research & Innovation, in partnership with The Oregon Clinical & Translational Research Institute (OCTRI), OHSU Technology Transfer and OHSU Collaborations and Entrepreneurship, are accepting proposals for basic or clinical research across the translational spectrum that directly addresses COVID-19 from all disciplines.

Grants will be awarded on a competitive basis, with budgets not to exceed $75,000 in direct costs (overhead costs not supported). Certain proposals may be eligible for additional funding. Projects will typically be supported for a 6-month period; predetermined milestones and quantitative metrics of success will be evaluated on a regular basis.

PROGRAM OVERVIEW

The BIP is designed to move research from bench-to-bedside by highlighting and prioritizing commercialization, or, "go-to-market" strategies. It provides resources such as funding, project management, entrepreneur education, and business mentoring to put technologies in the best possible position for follow-on funding and/or private investment.

APPLICATION PROCESS OVERVIEW

1. Complete a Technology Disclosure Form and submit to OHSU Technology Transfer (if not previously submitted).
2. Complete the COVID-19 Study Questionnaire. OHSU COVID-19 task force approval required for application to move forward.
3. Submit via REDCap here:
   a. Research plan no more than 5 pages long. References do not count toward page total.
   b. NIH 398 budget & budget justification
   c. NIH biosketches for PI and key personnel
   d. "Optional" Letters of support (up to 3)
4. Finalists will be invited to a Q&A with the review committee, after which, final funding decisions will be made.

CONTACT OCTRI

To learn more about this program please contact:

Jonathan Jubera, M.B.A.
OCTRI Awards Project Manager
jubera@ohsu.edu

KEY DATES

Application deadline: 4/23/20
Finalist Q&A with reviewers: TBA

ELIGIBILITY

Applicants must meet OHSU Principal Investigator requirements

VISIT OUR WEB PAGE

www.ohsu.edu/octri-bip

ACKNOWLEDGMENTS

This funding mechanism is supported by the OHSU Foundation, OHSU Technology Transfer, OHSU Collaborations & Entrepreneurship, and the National Center for Advancing Translational Science (UL1TR002369)
**REVIEW CRITERIA**

- **Leverage Pilot Funding:** How can this funding be leveraged to make significant strides quickly towards solving COVID-19 related problems? Have types of follow-on funding been identified?
- **Impact to Human Health:** To what degree does the proposed work directly address problems associated with COVID-19? How significant are these problems within the context of the pandemic?
- **Market Need Addressed:** What is the market need (number of patients likely affected, expected savings in health care/societal expenditures, etc.)? How many potential applications or products could come from the proposed technology?
- **Project Design and Feasibility:** Is the proposed work feasible? What types of expertise will be leveraged to move the technology forward? What are the potential barriers, and what is the plan to overcome them?
- **Innovation and Novelty:** Is the technology novel, useful, non-obvious, and enabled? Have any patents been filed? Are there other types of intellectual property that could be protected (copyrights, know-how, etc.)?
- **Commercialization Potential:** What is the commercialization strategy and path(s) to secure additional funding? Are there target entities identified as potential partners or licensees? Is there interest and potential for creating a start-up?
- **Strength of Team:** Do the investigators have the requisite skills and experience to carry out the project successfully.

**CONFIDENTIALITY**

All application materials are treated as confidential documents. Confidentiality agreements are in place with all members of the review committee.

**POST-AWARD PROCESSES**

All award recipients will be required to submit progress reports using guidelines that will be provided at a later date.

**QUESTIONS?**

Please direct all questions Jonathan Jubera (jubera@ohsu.edu, 503-805-8179).